Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of Lanabecestat in healthy males
NCT02126514Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lanabecestat in Alzheimer's disease (AD), sponsored by AstraZeneca. Primary endpoints: Area under the concentration-time curve and Maximum observed concentration. Started May 2014; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02126514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126514.